AI is swiftly reshaping the pharmaceutical industry, transforming every facet from drug discovery to supply chain management with unparalleled speed and precision. The pace of adoption continues to accelerate, with projections that AI could unlock $60 – 110 billion in annual value for the industry (Mckinsey 2025).
Beyond Failure Prevention: How AI is Redesigning the Drug Discovery Pipline
AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with Vitalay Fomin of Numenos about biomarker discovery, patient stratification, and why the next breakthroughs come from breaking down data silos across diseases, modalities, and even species.



Write a comment ...